1. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available at: (last accessed 27 August 2019).

  1. Grulich AE, Guy R, Amin J, et al; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 2018;5:e629-37.

  1. Medland NA, Chow EPF, Read THR, et al. Incident HIV infection has fallen rapidly in men who have sex with men in Melbourne, Australia (2013–2017) but not in the newly arrived Asian-born. BMC Infect Dis 2018;18:410.

  1. Kirby Institute. Monitoring HIV pre-exposure prophylaxis uptake in Australia. PBS-subsidised HIV pre-exposure prophylaxis from April 2018 to December 2018. Issue 1. 1 June 2019. Sydney: The Kirby Institute, UNSW Sydney; 2019. Available at: (last accessed 3 September 2019).

  1. Kirby Institute. Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018.

  1. Ward JS, Hawke K, Guy RJ. Priorities for preventing a concentrated HIV epidemic among Aboriginal and Torres Strait Islander Australians. Med J Aust 2018;209:56.

  1. Heard S, Iversen J, Geddes L, Maher L. Australian NSP Survey National Data Report 2013-2017: prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. Sydney: Kirby Institute, UNSW Sydney; 2018.

  1. Poynten IM, Jin F, Prestage GP, Kaldor JM, Kippax S, Grulich AE. Defining high HIV incidence subgroups of Australian homosexual men: implications for conducting HIV prevention trials in low HIV prevalence settings. HIV Med 2010;11:635-41.

  1. Cornelisse VJ, Fairley CK, Stoove M, et al; PrEPX Study Team. Evaluation of preexposure (PrEP) eligibility criteria, using sexually transmissible infections as markers of human immunodeficiency virus (HIV) risk at enrollment in PrEPX, a large Australian HIV PrEP trial. Clin Infect Dis 2018;67:1847-52.

  1. Cohen MS, Chen YQ, McCauley M, et al; HPTN 052 Study Team. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375:830-9.

  1. Bavinton BR, Pinto AN, Phanuphak N, et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV 2018;5:e438-47.

  1. Rodger AJ, Cambiano V, Bruun T, et al; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019;393:2428-38.

  1. Darrow WW, Echenberg DF, Jaffe HW, et al. Risk factors for human immunodeficiency virus (HIV) infections in homosexual men. Am J Public Health 1987;77:479–83.

  1. Hook EW 3rd. Syphilis. Lancet 2017;389:1550–57.

  1. Vu NT, Maher L, Zablotska I. Amphetamine-type stimulants and HIV infection among men who have sex with men: implications on HIV research and prevention from a systematic review and meta-analysis. J Int AIDS Soc 2015;18:19273.

  1. Bui H, Zablotska-Manos I, Hammoud M, et al. Prevalence and correlates of recent injecting drug use among gay and bisexual men in Australia: results from the FLUX study. Int J Drug Policy 2018;55:222-30.

  1. Jin F, Hammoud MA, Maher L, et al. Age-related prevalence and twelve-month incidence of illicit drug use in a cohort of Australian gay and bisexual men: Results from the Flux Study. Drug Alcohol Depend 2018;188:175-9.

  1. Prestage G, Hammoud M, Jin F, Degenhardt L, Bourne A, Maher L. Mental health, drug use and sexual risk behavior among gay and bisexual men? Int J Drug Policy 2018;55:169-79.

  1. Hammoud M, Vaccher S, Jin F, et al. The new MTV generation: using Methamphetamine, Truvada, and Viagra to enhance sex and stay safe. Int J Drug Policy 2018;55:197-204.